The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
|Videos|April 10, 2018
Clinical Decisions in Non-Driver NSCLC
Clinical Decisions in Non-Driver NSCLC
Advertisement
- A 55-year old female presented with chronic cough and 10-lb weight loss
- PMH: never smoker; no family history of cancer; no known exposure to chemicals or asbestos
- Chest x-ray showed a 5.0-cm lesion in the left lower lobe with bulky lymphadenopathy
- Chest CT scan confirmed the presence of a lung mass and enlargement of the right hilar lymph node and bilateral mediastinal lymph nodes
- EUS-guided biopsy was performed
- Pathology revealed adenocarcinoma
- Molecular testing:
- FISH: negative for ALK translocation
- NGS: negative for EGFR, ROS1, RET, BRAF, KRAS
- IHC: PD-L1 expression in 0% of cells
- PET/CT imaging showed 18F-FDG uptake in the lung mass, right hilar lymph node, mediastinum, and left adrenal gland
- MRI of the brain was normal
- ECOG PS, 0
- The patient was started on therapy with carboplatin/pemetrexed and bevacizumab
- The regimen was well tolerated
- After 6 cycles, the patient had a good response
- She was continued on bevacizumab
- After 9 months on therapy, the patient developed cough and weight loss
- Follow-up imaging revealed multiple new lesions in the left adrenal gland and new liver metastases
- Patient was started on atezolizumab, planned for 12 months
Advertisement
Related to this article
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
SOT106 Receives New FDA FTD and ODD in Sarcoma
2
Iberdomide Doubles MRD-Negative CR Rate in Phase 3 EXCALIBER-RRMM Trial
3
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
4
IMS 2026 Day 3 Recap: Etentamig Outperforms Standard Therapy in RRMM Trial
5